Navigation Links
New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site
Date:2/21/2013

TAMPA, Florida (Feb. 21, 2013) Cardiovascular disease specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute affiliated with the University of South Florida announced they have enrolled their first patients into a clinical trial testing a novel gene therapy for the treatment of heart failure after ischemic injury. The therapy may promote the regeneration of heart tissue by encouraging the body to deploy more stem cells to the injury site.

Dr. Charles Lambert, Medical Director of Florida Hospital Pepin Heart Institute and Dr. Leslie Miller, Director of the USF Heart Institute, are leading the way for the randomized, placebo-controlled trial which spans 10 sites across the United States. The study, called the STOP-HF, will enroll 90 patients nationwide.

Heart failure (HF) can occur when the muscles of the heart become weakened and cannot pump blood sufficiently throughout the body. The injury is most often caused by inadequate blood flow to the heart resulting from chronic or acute cardiovascular disease, including heart attacks. Considerable scientific evidence has emerged over the past decade demonstrating the high therapeutic potential of regenerative medicine for a host of diseases. Heart failure is a leading cause of death, disability and hospitalization.

Dr. Charles Lambert is performing the gene therapy by direct injection into the heart using an investigational system in the catheterization laboratories at Florida Hospital Pepin Heart Institute.

"Pepin Heart and Dr. Kiran C. Patel Research Institute and USF are exploring and conducting leading-edge research to develop break-through treatments long before they are even available in other facilities," Dr. Lambert said. "Stem cells have the unique ability to develop into many different cell types, and in many tissues serve as an internal repair system, dividing essentially without limit to replenish other cells. This trial is unique in that it uses gene therapy to turn on a process leading to cell regeneration rather than simply administering stem cells directly."

The Pepin Heart Institute has a history of cardiovascular stem cell research as part of the NIH sponsored Cardiac Cell Therapy Research Network (CCTRN) as well as other active cell therapy trials. Locally, the STOP-HF trial is the first of several regenerative medicine clinical trials teaming the USF Heart Institute with Florida Hospital Pepin Heart Institute, which is adjacent to the USF Health campus.

"This is the beginning of a new era in cardiovascular therapies," said Dr. Leslie Miller, national principal investigator for the STOP-HF trial and professor of cardiovascualar sciences at the USF Health Morsani College of Medicine. "Targeted gene and cell therapies delivered directly into the heart hold promise for helping to regenerate tissue, reduce injury and restore heart function. USF Health, working with our partners, will find new ways to diagnose and treat patients, with the aim of reducing and ultimately harnessing the global impact of heart disease."

The trial, sponsored by Juventas Therapeutics, is a double blind, randomized, placebo-controlled Phase II study evaluating the safety and effectiveness of JVS-100 in patients with ischemic heart failure. JVS-100 is the name of the gene therapy that directs the heart muscle to produce Stromal cell-Derived Factor 1 (SDF-1), a protein that has been shown to repair damaged tissue in the body through the recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

Earlier this year, Juventas reported results from its Phase I study in Class III ischemic heart failure patients. In addition to meeting the primary safety endpoint, patients in the study who received the drug demonstrated clinically significant improvements in exercise levels at the 12 month mark.

Other prominent institutions participating in the multicenter trial include Columbia University Medical Center, The University of Utah, the Lindner Center for Research at the Christ Hospital, and the Minneapolis Heart Institute Foundation.


'/>"/>

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3303
University of South Florida (USF Health)
Source:Eurekalert  

Related biology news :

1. Cell therapy a little more concrete thanks to VIB research
2. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
3. Novel coronavirus well-adapted to humans, susceptible to immunotherapy
4. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
5. Compound stimulates tumor-fighting protein in cancer therapy
6. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
7. Pitt researchers reveal mechanism to halt cancer cell growth, discover potential therapy
8. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
9. BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection
10. Canada launches first gene therapy trial for Fabry disease
11. New way to kill lymphoma without chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):
(Date:6/26/2017)... ... 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , the ... healthcare information exchange and a statutory advisor to the U.S. Department of Health and ... of the National Coordinator for Health Information Technology, will deliver the keynote at its ...
(Date:6/23/2017)... ... ... Biova, LLC., the leader in water soluble egg membrane ingredients, announced today ... bring a wealth of scientific experience in the food, beverage, nutrition and dietary supplement ... of four major global companies in the last 4 decades. He has a ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical ... Physik Instrumente USA, have been selected as this year’s recipients of two top awards ... have been invited along with other honorees to accept their awards at a banquet ...
(Date:6/23/2017)... IN (PRWEB) , ... June 23, 2017 , ... ... voice for model aircraft flying hobbyists, and the University Aviation Association (UAA), the ... college students. The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through ...
Breaking Biology Technology: